Pazufloxacin

Intravenous
Abdominal infections, Abscess of liver, Cholecystitis, Cystitis, Endometriosis, Intra-abdominal infections, Lung abscess, Peritonitis, Pneumonia, Prostatitis, Pyelonephritis, Secondary infections in trauma, burns, or surgical wounds

Moderate to severe: 300 mg bid.

Hypersensitivity. Pregnancy.

Patient with convulsive disorder, epilepsy. Moderate to severe renal impairment.

Significant: Hypersensitivity reactions.
Gastrointestinal disorder: Diarrhoea, nausea, vomiting.
General disorders and administration site conditions: Inj site reactions (e.g. pain, erythema, swelling, induration, phlebitis).
Nervous system disorders: Rarely, convulsion.
Skin and subcutaneous tissue disorders: Rashes.

Description: Pazufloxacin is a fluoroquinolone antibacterial. It exerts its bactericidal activity by inhibiting both DNA gyrase and topoisomerase IV enzyme leading to increased antibacterial spectrum.
Pharmacokinetics:
Absorption: Time to peak plasma concentration: 30 minutes.
Distribution: Widely distributed throughout the body (e.g. phlegm, lungs, biliary tract, pleural fluid, genital organs, CSF).
Excretion: Via urine (89.5-93.8%, as unchanged drug). Terminal elimination half-life: 1.65-1.88 hours.

Source: National Center for Biotechnology Information. PubChem Database. Pazufloxacin, CID=65957, https://pubchem.ncbi.nlm.nih.gov/compound/Pazufloxacin (accessed on Jan. 22, 2020)

Quinolones

J01MA18 - pazufloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.

Buckingham R (ed). Pazufloxacin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/05/2018.